Harvard Bioscience (HBIO) Q2 FY26 earnings call

Harvard Bioscience delivered strong Q2 FY26 results, driven by double-digit revenue growth in its CMT and preclinical portfolios and robust demand from CRO customers. The company raised its full-year revenue outlook, reflecting commercial momentum and strategic execution. While product mix shifts impacted gross margin, management remains confident in long-term expansion through NPI platforms and recurring revenue growth, supported by Project Viking cost savings.